Chariot Ltd (AIM:CHAR, OTC:OIGLF) new well in Morocco promises to de-risk and unlock other similar nearby projects, stockbroker Panmure Gordon highlighted following the start of drilling.
This morning, in a statement, Chariot confirmed the start of drilling on the OBA-1 well, on the Dartois prospect located in the Loukos Onshore licence.
Shares of Faron Pharmaceuticals Limited (AIM:FARN) surged 13% following positive initial results from phase II of its BEXMAB trial.
The trial focuses on treating myelodysplastic syndrome (MDS) patients who have failed hypomethylating agent (HMA) therapy.
Itaconix PLC (AIM:ITX, OTCQB:ITXXF) jumped almost 8% on Monday morning after confirming new orders in Europe and the US and that profit margins were improving.
Total gross profit margins for the year so far have exceeded 35%, non-executive chair Peter Nieuwenhuizen said ahead of the company’s annual meeting on Monday.
Shares of Arecor Therapeutics PLC (AIM:AREC) surged 11% in early trading following impressive phase I trial results for its ultra-concentrated, ultra-rapid-acting insulin, AT278.
The study, focusing on overweight and obese individuals with Type 2 diabetes, showed AT278's superior absorption and glucose-lowering effects compared to NovoRapid and Humulin R U-500.
Bradda Head Lithium Ltd (AIM:BHL, OTC:BHLIF, TSX-V:BHLI) said it had agreed to settle regarding a fraudulent payment notified in March 2022 with the payment amounting to gross recovery of approximately 40% of the total funds stolen.
The agreement provides for no admission of liability by either party involved and the full commercial terms of the settlement are subject to strict confidentiality obligations on both parties so it will not be making any further comment on this matter.
Metals One PLC (AIM:MET1) has raised a gross £895,000 through a placing and subscription at 1p per share to support the development of the Finland - Black Schist project in Norway.
Proceeds from the placing will allow for the termination of the farm-in agreement with Gunsynd and provide Metals One with the option to regain 100% ownership of its cornerstone Black Schist Project.
Arecor Therapeutics PLC (AIM:AREC) has announced impressive results from its phase I trial of AT278, an ultra-concentrated, ultra-rapid-acting insulin. The trial focused on overweight and obese people with Type 2 diabetes.
AT278 demonstrated a significantly faster absorption and glucose-lowering effect compared with existing current best-in-class products NovoRapid and Humulin R U-500. This result confirms the findings from a previous trial with Type 1 diabetes patients, showing that AT278 works effectively regardless of diabetes type or body mass index (BMI).
Chariot Ltd (AIM:CHAR, OTC:OIGLF) told investors it has started drilling the OBA-1 well, on the Dartois prospect located in the Loukos Onshore licence, in Morocco.
The Dartois target holds an estimated recoverable prospective resource of 12 billion cubic feet (Bcf).
Faron Pharmaceuticals Limited (AIM:FARN) has announced initial positive results from phase II of its BEXMAB trial of its cancer treatment Bexmarilimab, indicating significant progress in treating myelodysplastic syndrome (MDS) patients who have previously failed hypomethylating agent (HMA) therapy.
This comes after earlier study results showed promising outcomes.